Seyed Massood Nabavi - Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Mehrnoosh Mehrabani - Arya group for treatment and research in multiple sclerosis, Tehran, Iran.
Shahedeh Karimi - Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Ehsan Mohammadianinejad - Neurology department, Jondishapour University of medical sciences, Tehran, Iran.
Mehran Ghafari - Neurology department, Shahid Beheshti University of medical sciences, Tehran, Iran.
Maryam Dastoorpour - Epidemiology and public health department, Jondishapour University of medical sciences, Tehran, Iran.

Coronavirus disease ۲۰۱۹ (COVID-۱۹) is more common in patients with multiple sclerosis because of receiving immunosuppressive or immunomodulating disease-modifying therapies (DMTs). On the other hand, some of these drugs may interact on COVID-۱۹ vaccines. In this commentary, first we introduce some available COVID-۱۹ vaccines and then discuss the effect of different DMTs on immune responses after vaccination. We have not found a connection between vaccination and MS relapses, so we suggest that the benefit from the vaccine outweighs any potential risks in these patients.

Coronavirus disease ۲۰۱۹ (COVID-۱۹), Multiple sclerosis, Vaccination, Disease-modifying therapies (DMTs)